300482 万孚生物
已收盘 01-28 15:00:00
资讯
新帖
简况
万孚生物公布国际专利申请:“核酸检测卡盒及核酸检测方法”
证券之星 · 05:48
万孚生物公布国际专利申请:“核酸检测卡盒及核酸检测方法”
万孚生物:2026年业务的显著提升
证券之星 · 01-28 20:51
万孚生物:2026年业务的显著提升
万孚生物:公司国际部持续推动海外业务的本地化运营
证券日报网 · 01-27 21:09
万孚生物:公司国际部持续推动海外业务的本地化运营
万孚生物:持续提升基层医疗机构、区域型体检中心的渗透率
证券之星 · 01-27 16:48
万孚生物:持续提升基层医疗机构、区域型体检中心的渗透率
万孚生物:始终坚持“稳健经营与高质量发展并重”的长期战略
证券之星 · 01-27 16:24
万孚生物:始终坚持“稳健经营与高质量发展并重”的长期战略
万孚生物:呼吸道检测产品可覆盖常见呼吸道病原体
证券之星 · 01-27 16:12
万孚生物:呼吸道检测产品可覆盖常见呼吸道病原体
万孚生物(300482)披露债券持有人可转债持有比例变动达10%的公告,1月26日股价上涨16.23%
证券之星 · 01-26 22:51
万孚生物(300482)披露债券持有人可转债持有比例变动达10%的公告,1月26日股价上涨16.23%
万孚生物涨16.23%,太平洋二个月前给出“买入”评级
证券之星 · 01-26 15:52
万孚生物涨16.23%,太平洋二个月前给出“买入”评级
万孚生物(300482)披露2026年第二次临时股东会决议公告,1月23日股价上涨2.61%
证券之星 · 01-23
万孚生物(300482)披露2026年第二次临时股东会决议公告,1月23日股价上涨2.61%
万孚生物:布局AI医疗生态并推动多场景落地
证券之星 · 01-21
万孚生物:布局AI医疗生态并推动多场景落地
股市必读:万孚生物(300482)1月20日董秘有最新回复
证券之星 · 01-21
股市必读:万孚生物(300482)1月20日董秘有最新回复
万孚生物:相关产品可覆盖大多数毒株
证券之星 · 01-20
万孚生物:相关产品可覆盖大多数毒株
万孚生物:公司暂无相关产品布局
证券之星 · 01-20
万孚生物:公司暂无相关产品布局
万孚生物(300482)披露向下修正可转换公司债券转股价格议案获股东会通过,1月15日股价上涨1.12%
证券之星 · 01-15
万孚生物(300482)披露向下修正可转换公司债券转股价格议案获股东会通过,1月15日股价上涨1.12%
股市必读:万孚生物(300482)预计2025年全年扣非后净利润亏损750万元至1500万元
证券之星 · 01-12
股市必读:万孚生物(300482)预计2025年全年扣非后净利润亏损750万元至1500万元
万孚生物将交上市以来最差成绩单
市场资讯 · 01-11
万孚生物将交上市以来最差成绩单
万孚生物(300482)披露2025年度业绩预告,1月9日股价上涨1.24%
证券之星 · 01-09
万孚生物(300482)披露2025年度业绩预告,1月9日股价上涨1.24%
万孚生物:预计2025年全年扣非后净利润亏损750万元至1500万元
证券之星 · 01-09
万孚生物:预计2025年全年扣非后净利润亏损750万元至1500万元
万孚生物(300482.SZ)发预减,预计2025 年度归母净利润4600万元至6900万元,下降87.71%至91.81%
智通财经 · 01-09
万孚生物(300482.SZ)发预减,预计2025 年度归母净利润4600万元至6900万元,下降87.71%至91.81%
股市必读:万孚生物(300482)1月7日董秘有最新回复
证券之星 · 01-08
股市必读:万孚生物(300482)1月7日董秘有最新回复
加载更多
公司概况
公司名称:
广州万孚生物技术股份有限公司
所属行业:
医药制造业
上市日期:
2015-06-30
主营业务:
广州万孚生物技术股份有限公司的主营业务是快速诊断试剂及配套仪器的研发、生产智造、营销及服务。公司的主要产品是妊娠及优生优育检测、传染病检测、毒品(药物滥用)检测、慢性疾病检测。公司作为中国POCT领域的龙头企业公司先后荣获国家火炬计划重点高新技术企业、国家生物工程高技术产业化示范基地、国家知识产权优势企业、世界海关组织AEO高级认证企业、国家认定企业技术中心、博士后科研工作站、国家知识产权示范企业、广东省第一批制造业单项冠军企业等资质。
发行价格:
16.00
{"stockData":{"symbol":"300482","market":"SZ","secType":"STK","nameCN":"万孚生物","latestPrice":22.67,"timestamp":1769583810000,"preClose":24.72,"halted":0,"volume":40261167,"delay":0,"changeRate":-0.0829,"floatShares":430000000,"shares":468000000,"eps":0.5543,"marketStatus":"已收盘","change":-2.05,"latestTime":"01-28 15:00:00","open":23.83,"high":23.96,"low":22.63,"amount":933000000,"amplitude":0.0538,"askPrice":22.68,"askSize":441,"bidPrice":22.67,"bidSize":84,"shortable":0,"etf":0,"ttmEps":0.5543,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769650200000},"marketStatusCode":5,"adr":0,"adjPreClose":24.72,"symbolType":"stock","openAndCloseTimeList":[[1769563800000,1769571000000],[1769576400000,1769583600000]],"highLimit":27.19,"lowLimit":22.25,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":468084909,"isCdr":false,"pbRate":2.15,"roa":"--","peRate":40.89843,"roe":"2.47%","epsLYR":1.21,"committee":0.535333,"marketValue":10611000000,"turnoverRate":0.0935,"status":1,"floatMarketCap":9757000000},"requestUrl":"/m/hq/s/300482","defaultTab":"news","newsList":[{"id":"2607725585","title":"万孚生物公布国际专利申请:“核酸检测卡盒及核酸检测方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2607725585","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607725585?lang=zh_cn&edition=full","pubTime":"2026-01-29 05:48","pubTimestamp":1769636924,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示万孚生物(300482)公布了一项国际专利申请,专利名为“核酸检测卡盒及核酸检测方法”,专利申请号为PCT/CN2025/107061,国际公布日为2026年1月22日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来万孚生物已公布的国际专利申请2个。结合公司2025年中报财务数据,2025上半年公司在研发方面投入了1.74亿元,同比减11.7%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900003473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0046","300482"],"gpt_icon":0},{"id":"2606671995","title":"万孚生物:2026年业务的显著提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2606671995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606671995?lang=zh_cn&edition=full","pubTime":"2026-01-28 20:51","pubTimestamp":1769604683,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物01月27日在投资者关系平台上答复投资者关心的问题。投资者提问:除新的增长点外,支撑基本盘的传统核心业务在2026年的展望如何?公司判断这部分业务何时能结束下滑、恢复稳定增长?驱动因素是国内IVD行业整体复苏,还是公司产品升级带来的份额提升?万孚生物回复:尊敬的投资者您好,2026年,公司会坚持客户导向,坚定创新和AI驱动,业务从POC向IVD拓展,加速出海布局,实现2026年业务的显著提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800040638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0197","BK0239","BK0046"],"gpt_icon":0},{"id":"2606738310","title":"万孚生物:公司国际部持续推动海外业务的本地化运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2606738310","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606738310?lang=zh_cn&edition=full","pubTime":"2026-01-27 21:09","pubTimestamp":1769519340,"startTime":"0","endTime":"0","summary":"证券日报网讯1月27日,万孚生物在互动平台回答投资者提问时表示,公司国际部持续推动海外业务的本地化运营,对公司业绩影响请参照公司未来定期报告。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-27/doc-inhiuixr8018141.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-27/doc-inhiuixr8018141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","300482","BK0239","BK0197"],"gpt_icon":0},{"id":"2606043132","title":"万孚生物:持续提升基层医疗机构、区域型体检中心的渗透率","url":"https://stock-news.laohu8.com/highlight/detail?id=2606043132","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606043132?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:48","pubTimestamp":1769503697,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物01月27日在投资者关系平台上答复投资者关心的问题。是否计划扩大药店覆盖度,打造“健康检测专区”或开展店员专业培训?公司致力于持续提升基层医疗机构、区域型体检中心的渗透率,通过不断扩充渠道合作伙伴,夯实国内业务的增长基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700027672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300482","BK0046","BK0197"],"gpt_icon":0},{"id":"2606201339","title":"万孚生物:始终坚持“稳健经营与高质量发展并重”的长期战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2606201339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606201339?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:24","pubTimestamp":1769502262,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物01月27日在投资者关系平台上答复投资者关心的问题。研发投入是公司长期核心竞争力的来源。公司会在保证财务安全边际的前提下,保持战略定力,聚焦高产出、高壁垒的关键技术领域进行精准投入,以技术创新驱动经营质量的持续提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700026353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300482","BK0046","BK0239"],"gpt_icon":0},{"id":"2606184209","title":"万孚生物:呼吸道检测产品可覆盖常见呼吸道病原体","url":"https://stock-news.laohu8.com/highlight/detail?id=2606184209","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606184209?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:12","pubTimestamp":1769501538,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物(300482)01月27日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!2025年底获批的呼吸道六联检、MiniTLA流水线等重磅新品,目前国内市场落地进度、客户反馈及2026年销售目标如何?万孚生物回复:尊敬的投资者您好,公司呼吸道检测产品可覆盖常见呼吸道病原体,适配口咽拭子样本类型,搭配公司配套仪器可满足临床高发呼吸道感染性疾病的快速通量筛查需求。公司将持续关注业务推进情况,具体对公司业务影响请留意后期公司定期报告。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700024980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0046","300482"],"gpt_icon":0},{"id":"2606324999","title":"万孚生物(300482)披露债券持有人可转债持有比例变动达10%的公告,1月26日股价上涨16.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606324999","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606324999?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:51","pubTimestamp":1769439087,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘,万孚生物报收于25.56元,较前一交易日上涨16.23%,最新总市值为119.64亿元。万孚生物近日发布《关于债券持有人可转债持有比例变动达10%的公告》。公司收到优美利投资告知函,其管理的基金于2025年12月12日至2026年1月26日期间通过集中竞价方式减持“万孚转债”906,226张,占发行总量的15.10%。本次减持后,优美利投资持有338,871张,占发行总量比例由20.75%降至5.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600036850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0046","BK0239","BK0197"],"gpt_icon":0},{"id":"2606297155","title":"万孚生物涨16.23%,太平洋二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2606297155","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606297155?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:52","pubTimestamp":1769413945,"startTime":"0","endTime":"0","summary":"今日万孚生物(300482)涨16.23%,收盘报25.56元。2025年11月18日,太平洋研究员谭紫媚,李啸岩发布了对万孚生物的研报《万孚生物:海外业务进展顺利,国内短暂承压》,该研报对万孚生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为60.5%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为中泰证券的江琦。万孚生物(300482)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600015285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","300482"],"gpt_icon":0},{"id":"2605904406","title":"万孚生物(300482)披露2026年第二次临时股东会决议公告,1月23日股价上涨2.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605904406","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605904406?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:41","pubTimestamp":1769179277,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,万孚生物报收于21.99元,较前一交易日上涨2.61%,最新总市值为102.93亿元。该股当日开盘21.77元,最高22.01元,最低21.48元,成交额达2.2亿元,换手率为2.34%。万孚生物于2026年1月23日召开2026年第二次临时股东会,审议通过补选王菊芳女士为第五届董事会独立董事、选举汪洋先生为第五届董事会非独立董事的议案。两项议案均获高票通过,王菊芳、汪洋分别当选独立董事与非独立董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300482","BK0239","BK0046"],"gpt_icon":0},{"id":"2605210257","title":"万孚生物:布局AI医疗生态并推动多场景落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2605210257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605210257?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:51","pubTimestamp":1768999897,"startTime":"0","endTime":"0","summary":"万孚生物回复:尊敬的投资者您好,公司自2018年开始布局AI医疗,形成“并购+院端+C端”并举的AI医疗生态,目标是取得更多注册证获批及商业模式突破,中长期成为国内AI医疗领域领先企业。其在CT影像和超声影像AI检测软件方面处于领先地位,目前共持有6张三类证。在C端/消费端的万孚健康小程序已上线,可以AI自动识别呼吸道、消化道、血液传染病检测结果,并支持形成个人健康档案,助力推动消费端业务增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100038906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0046","159891","BK0197","BK0239"],"gpt_icon":0},{"id":"2605143017","title":"股市必读:万孚生物(300482)1月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605143017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605143017?lang=zh_cn&edition=full","pubTime":"2026-01-21 02:51","pubTimestamp":1768935068,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘,万孚生物报收于21.83元,下跌0.32%,换手率2.47%,成交量10.62万手,成交额2.34亿元。董秘最新回复投资者: 公司脑机接口目前进展如何?董秘: 尊敬的投资者您好,公司相关产品可以覆盖市场上大多数毒株,公司会时刻关注业务机会,相关事项对公司业绩影响须留意后续公司定期报告当日关注点来自交易信息汇总:1月20日主力资金净流入491.81万元,显示主力对万孚生物股票的积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100001210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300482"],"gpt_icon":0},{"id":"2604956531","title":"万孚生物:相关产品可覆盖大多数毒株","url":"https://stock-news.laohu8.com/highlight/detail?id=2604956531","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604956531?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:00","pubTimestamp":1768899637,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物(300482)01月20日在投资者关系平台上答复投资者关心的问题。投资者提问:美国CDC 2026年1月周报上说流感主力毒株是H3N2 K型分支,请问公司检测产品是否有能力检测?应对美国流感季,公司有哪些运营举措?万孚生物回复:尊敬的投资者您好,公司相关产品可以覆盖市场上大多数毒株,公司会时刻关注业务机会,相关事项对公司业绩影响须留意后续公司定期报告以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000026025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0239","BK0046","BK0197"],"gpt_icon":0},{"id":"2604193064","title":"万孚生物:公司暂无相关产品布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2604193064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604193064?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:54","pubTimestamp":1768899245,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物(300482)01月20日在投资者关系平台上答复投资者关心的问题。投资者提问:公司脑机接口目前进展如何?有没有量产?万孚生物回复:尊敬的投资者您好,公司暂无相关产品布局,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000025835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","BK0239","300482"],"gpt_icon":0},{"id":"2603603861","title":"万孚生物(300482)披露向下修正可转换公司债券转股价格议案获股东会通过,1月15日股价上涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603603861?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:36","pubTimestamp":1768469764,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘,万孚生物报收于21.64元,较前一交易日上涨1.12%,最新总市值为101.29亿元。根据公司近日发布的公告,广州万孚生物技术股份有限公司于2026年1月14日召开2026年第一次临时股东会,审议通过《关于董事会提议向下修正可转换公司债券转股价格的议案》和《关于修订<公司章程>及相关议事规则的议案》。两项议案均获得出席股东所持表决权的三分之二以上通过。现场及网络投票股东共计380人,代表股份占公司有表决权股份总数的44.7831%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500029025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300482","BK0046","BK0197"],"gpt_icon":0},{"id":"2602314550","title":"股市必读:万孚生物(300482)预计2025年全年扣非后净利润亏损750万元至1500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602314550","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602314550?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:23","pubTimestamp":1768159388,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,万孚生物报收于20.42元,上涨1.24%,换手率1.26%,成交量5.41万手,成交额1.1亿元。业绩披露要点业绩预告万孚生物发布业绩预告,预计2025年全年扣非后净利润亏损750万元至1500万元。公司公告汇总广州万孚生物技术股份有限公司2025年度业绩预告广州万孚生物技术股份有限公司发布2025年度业绩预告,预计归属于上市公司股东的净利润为4,600万元至6,900万元,同比下降87.71%至91.81%;扣除非经常性损益后的净利润为-1,500万元至-750万元,同比下降101.51%至103.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482"],"gpt_icon":0},{"id":"2602631605","title":"万孚生物将交上市以来最差成绩单","url":"https://stock-news.laohu8.com/highlight/detail?id=2602631605","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602631605?lang=zh_cn&edition=full","pubTime":"2026-01-11 23:28","pubTimestamp":1768145280,"startTime":"0","endTime":"0","summary":" 上市10年,万孚生物将交出一份上市以来业绩最差成绩单。 万孚生物近日发布的业绩预告显示,2025年预计归属净利润为4600万—6900万元,同比预降87.71%—91.81%。 此外,万孚生物方面预计,2025年扣非净利润为-750万—-1500万元,同比由盈转亏,这也将是公司上市以来首度出现扣非净利润亏损的情况。 值得一提的是,2025年,万孚生物在海外市场取得不错的成绩。万孚生物方面表示,国内市场,基层医疗市场胶体金和荧光产品线收入下滑,盈利减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-01-11/doc-inhfyhii7388867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0197","BK0239","300482","BK0046"],"gpt_icon":0},{"id":"2602323372","title":"万孚生物(300482)披露2025年度业绩预告,1月9日股价上涨1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602323372","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602323372?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:48","pubTimestamp":1767970093,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,万孚生物报收于20.42元,较前一交易日上涨1.24%,最新总市值为95.58亿元。该股当日开盘20.2元,最高20.45元,最低20.17元,成交额达1.1亿元,换手率为1.26%。公司于近日发布2025年度业绩预告,预计归属于上市公司股东的净利润为4,600万元至6,900万元,同比下降87.71%至91.81%;扣除非经常性损益后的净利润为-1,500万元至-750万元,同比下降101.51%至103.02%。具体数据以2025年年度报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900041373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300482"],"gpt_icon":0},{"id":"2602324899","title":"万孚生物:预计2025年全年扣非后净利润亏损750万元至1500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602324899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602324899?lang=zh_cn&edition=full","pubTime":"2026-01-09 18:00","pubTimestamp":1767952836,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物发布业绩预告,预计2025年全年扣非后净利润亏损750万元至1500万元。万孚生物2025年三季报显示,前三季度公司主营收入16.9亿元,同比下降22.52%;归母净利润1.34亿元,同比下降69.32%;扣非净利润8264.16万元,同比下降78.67%;其中2025年第三季度,公司单季度主营收入4.45亿元,同比下降26.66%;单季度归母净利润-5545.91万元,同比下降169.21%;单季度扣非净利润-7090.64万元,同比下降213.09%;负债率16.42%,投资收益1374.5万元,财务费用2847.74万元,毛利率60.3%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900029648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482"],"gpt_icon":0},{"id":"2602269783","title":"万孚生物(300482.SZ)发预减,预计2025 年度归母净利润4600万元至6900万元,下降87.71%至91.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602269783","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602269783?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:58","pubTimestamp":1767949102,"startTime":"0","endTime":"0","summary":"智通财经APP讯,万孚生物(300482.SZ)披露2025 年度业绩预告,公司预计归属于上市公司股东的净利润4600万元至6900万元,同比下降87.71%至91.81%;扣除非经常性损益后的净亏损750万元至1500万元。公告称,公司主营业务收入同比下滑,主要原因是国内收入下滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300482"],"gpt_icon":0},{"id":"2601388936","title":"股市必读:万孚生物(300482)1月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601388936","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601388936?lang=zh_cn&edition=full","pubTime":"2026-01-08 01:49","pubTimestamp":1767808150,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘,万孚生物报收于20.0元,下跌0.84%,换手率0.91%,成交量3.92万手,成交额7873.74万元。公司公告汇总第五届董事会第二十次会议决议公告广州万孚生物技术股份有限公司于2026年1月6日召开第五届董事会第二十次会议,审议通过补选王菊芳女士为第五届董事会独立董事、选举汪洋先生为第五届董事会非独立董事的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800000890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300482","BK0046","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1769640832706,"stockEarnings":[{"period":"1week","weight":0.0413},{"period":"1month","weight":0.1549},{"period":"3month","weight":0.0683},{"period":"6month","weight":-0.0644},{"period":"1year","weight":0.0367},{"period":"ytd","weight":0.1478}],"compareEarnings":[{"period":"1week","weight":0.0083},{"period":"1month","weight":0.0469},{"period":"3month","weight":0.0412},{"period":"6month","weight":0.1661},{"period":"1year","weight":0.2771},{"period":"ytd","weight":0.046}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州万孚生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42360人(较上一季度减少5.59%)","perCapita":"10160股","listingDate":"2015-06-30","address":"广东省广州市黄埔区科学城荔枝山路8号","registeredCapital":"46808万元","survey":" 广州万孚生物技术股份有限公司的主营业务是快速诊断试剂及配套仪器的研发、生产智造、营销及服务。公司的主要产品是妊娠及优生优育检测、传染病检测、毒品(药物滥用)检测、慢性疾病检测。公司作为中国POCT领域的龙头企业公司先后荣获国家火炬计划重点高新技术企业、国家生物工程高技术产业化示范基地、国家知识产权优势企业、世界海关组织AEO高级认证企业、国家认定企业技术中心、博士后科研工作站、国家知识产权示范企业、广东省第一批制造业单项冠军企业等资质。","listedPrice":16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万孚生物(300482)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万孚生物,300482,万孚生物股票,万孚生物股票老虎,万孚生物股票老虎国际,万孚生物行情,万孚生物股票行情,万孚生物股价,万孚生物股市,万孚生物股票价格,万孚生物股票交易,万孚生物股票购买,万孚生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万孚生物(300482)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}